等待開盤 02-20 09:30:00 美东时间
-0.115
-0.32%
BRIEF-Meijer Announces New Affordable Access To GLP-1 Medications Feb 10 (Reuters) - Meijer Inc [RIC:RIC:MEIJR.UL]: MEIJER ANNOUNCES NEW AFFORDABLE ACCESS TO GLP-1 MEDICATIONS MEIJER INC - WEGOVY OR OZEMPIC INJECTION PENS FOR $199 PER MONTH FOR FIRST TWO MONTHS MEIJER INC: ELIGIBLE PATIENTS CAN ACCE
02-10 22:39
President Donald Trump may be creating investment opportunities in themes and helping put an emphasize thematic ETFs.
01-28 06:05
Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
2025-11-25 01:06
外资又来唱多!大摩称中国股市有望继续上涨;美联储12月降息概率一降再降,现已接近40%;拼多多、小米集团今日发财报>>
2025-11-18 08:23
Nov 17 (Reuters) - Novo Nordisk A/S NOVOb.CO: NOVO NORDISK LAUNCHES INTRODUCTORY SELF-PAY OFFER FOR WEGOVY® AND OZEMPIC® FOR $199 PER MONTH NOVO NORDISK - LOWERING PRICE OF WEGOVY(®) AND OZEMPIC(®) FO...
2025-11-17 20:50
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
2025-10-31 04:04
In paragraph 8, removes reference to the layoff of a strategic communications manager Novo Nordisk lays off staff at Clayton, NC plant, posts show Clayton site crucial for Wegovy production, U.S. expa...
2025-10-07 13:00
Sept 17 (Reuters) - Wisp: WISP: EXPANSION OF WEIGHT CARE VERTICAL, DELIVERING NAME-BRAND GLP-1S DIRECTLY TO OVER 1.5 MILLION PATIENTS WISP: PRICED OZEMPIC, WEGOVY, MOUNJARO AT $598, $558, $489 PER MON...
2025-09-17 21:00
Aug 18 (Reuters) - Novo Nordisk A/S NOVOb.CO: NOVO NORDISK LOWERS COST OF OZEMPIC® TO $499 PER MONTH FOR SELF-PAYING PATIENTS, IN SUPPORT OF PATIENT ACCESS TO AUTHENTIC, FDA-APPROVED SEMAGLUTIDE MEDIC...
2025-08-18 22:32
BOZEMAN, Mont.-- Fair Isaac Corporation (NYSE: FICO) has announced its intention to offer $1.5 billion in aggregate principal amount of Senior Notes due 2033. These Notes will be senior unsecured obli...
2025-05-08 20:45